MedPath

Evaluation of a Novel Electronic Transanal Irrigation System - Navina™ Smart

Not Applicable
Completed
Conditions
Neurogenic Bowel
Interventions
Device: Navina Smart
Registration Number
NCT02709395
Lead Sponsor
Wellspect HealthCare
Brief Summary

This study is designed as an open, prospective, single arm, multicenter study in order to investigate patient satisfaction, perception and compliance for the novel Navina Smart, a transanal irrigation (TAI) system. Approximately 30 male and female subjects who are currently practicing TAI, will be followed during a 4-week period of use of Navina Smart. Observational data on satisfaction, perception, compliance, bowel regimen, TAI therapy and TAI frequency will be collected via patient reported outcome (PRO) questionnaires.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  1. Provision of informed consent
  2. Males and females, aged 18 years and over
  3. Practice TAI since at least 2 months and at least two times per week
  4. Able to read and fill out a paper PRO questionnaire as judged by the principal investigator or a sub-investigator
Exclusion Criteria
  1. Any confirmed or suspected diagnosis of anal or rectal stenosis, active inflammatory bowel disease, acute diverticulitis, severe diverticulosis, colorectal cancer, ischemic colitis, history of life-threatening autonomic dysreflexia, bleeding disorders, unspecified peri-anal conditions
  2. Untreated rectal impaction
  3. Any radiotherapy to the pelvis
  4. Any current treatment with anticoagulants (not including aspirin or clopidogrel)
  5. Any current treatment with long-term systemic steroid medication (not including inhalation agents and/ or local topical treatment)
  6. Any prior rectal or colonic surgery (not including anal procedures >3 months ago, e.g. haemorrhoid excision)
  7. Anal, rectal and/or colonic endoscopic polypectomy within the previous 4 weeks
  8. Overt or planned pregnancy
  9. Ongoing symptomatic urinary tract infection as judged by the principal investigator or a sub-investigator
  10. Diagnosed psychiatric illness, considered as unstable by the principal investigator or a sub-investigator
  11. Involvement in the planning and conduct of the study (applies to both Wellspect HealthCare staff and staff at the study site)
  12. Previous enrolment in the present study
  13. Participation in another clinical study within the last 30 days that may interfere with the present study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Navina SmartNavina SmartNavina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
Primary Outcome Measures
NameTimeMethod
Questionnaire Measuring Subjects' Satisfaction of Navina Smart4 weeks

PRO Questionnaire, completed by each subject after 4 weeks of using Navina Smart, collecting data on subject's assessment of satisfaction when using the study device.

Satisfaction was assessed in a range of ways through different questions to be answered by each subject. For example each subject received the question "If possible, would you consider continuing using the Navina Smart system?"

Questionnaire Measuring Subjects' Perception of Navina Smart4 weeks

PRO Questionnaire, completed by each subject after 4 weeks of using Navina Smart, collecting data on subject's assessment of perception when using the study device.

For example, each subject answered the following question regarding perception: "How satisfied are you with the Navina Smart System?"

Questionnaire Measuring Subjects' Compliance of Navina Smart4 weeks

PRO Questionnaire, completed by each subject after 4 weeks of using Navina Smart, collecting data on subject's compliance towards the study device.

For example, each subject answered the following question "Did you use the Navina Smart system for 4 weeks?"

Secondary Outcome Measures
NameTimeMethod
Adverse Events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) Related to Navina Smart4 weeks

Total numbers and types of AEs, ADEs and SAEs observed by the study staff or spontaneously reported from the patient.

Trial Locations

Locations (2)

Gastrointestinal Physiology Unit, University College London Hospital

🇬🇧

London, United Kingdom

Neurologiska kliniken, Karolinska Universitetssjukhuset Solna

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath